71
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The 1999 WHO-ISH Guidelines for the Management of Hypertension - New targets, new treatment and a comprehensive approach to total cardiovascular risk reduction

Pages 3-5 | Published online: 08 Jul 2009

  • Zanchetti A. A re-examination of stepped-care: a retro-spective and a prospective. J Cardiovasc Pharmacol 1985; 7 (suppl 2): 5126–5131.
  • Opie LH. Individualised selection of antihypertensive ther-apy. Drugs 1993; 46 (suppl 2): 142–148.
  • Joint National Committee on Prevention, Detection, Evalu-ation, and Treatment of High Blood Pressure. The sixth re-port of the Joint National Committee on Prevention, De-tection, Evaluation, and treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446.
  • World Health Organization/International Society of Hyper-tension Fifth Mild Hypertension Conference. The 1989 guidelines for the management of mild hypertension. Memorandum from a WHO-ISH meeting. J Hypertens 1989; 7: 689–693.
  • Zanchetti A, Chalmers J, Arakawa K, Gyarfas I, Hamet P, Hansson L, Julius S, MacMahon S, Mancia G, Ménard J, Omae T, Reid J, Safar M. The 1993 guidelines for the management of mild hypertension: Memorandum from a WHO-ISH meeting. Blood Press 1993; 2: 86–100.
  • Guidelines Sub-Committee. 1999 World Health Organiza-tion — International Society of Hypertension guidelines for the management of hypertension. Blood Press 1999; 8 (suppl 1): 9–43.
  • Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elm-feldt D, Ménard J, Julius S, Rahn KH, Wedel H, Wester-ling S for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
  • UK Prospective Diabetes Study Group. Tight blood pres-sure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
  • Goldberg Al, Dunlay MC, Sweet CS. Safety and tolerab-ility of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibi-tors for the treatment of systemic hypertension. Am J Car-diol 1995; 75: 793–795.
  • Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation an-giotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53–59.
  • Malmqvist K. In hypertensive women candesartan cilexetil lowers blood pressure more and causes less adverse events compared to enalapril and hydrochlorothiazide: the CANDHY-2 Study. International Forum on Angiotensin II Receptor Antagonism, Monte Carlo, January 26–30, 1999 (Poster).
  • Chalmers J. Personal view: The national consensus confer-ence — not always what it seems. Blood Press 1994; 3: 4–6.
  • Hansson L, Hedner T, Jern S. After SHEP, STOP and MRC — New WHO/ISH guidelines for the management of mild hypertension. Blood Press 1993; 2: 83–84.
  • Anonymous. The hidden epidemic of cardiovascular dis-ease (editorial). Lancet 1998; 352: 1795.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.